|
MechanismPDE5A inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
CMS203片单剂量给药在男性勃起功能障碍(ED)患者中药物效应动力学(PD)的随机、双盲、阳性和安慰剂对照IIa期临床研究
[Translation] A randomized, double-blind, positive and placebo-controlled phase IIa clinical study on the pharmacodynamics (PD) of a single dose of CMS203 tablets in male patients with erectile dysfunction (ED)
主要目的评估不同剂量的CMS203片对阴茎勃起功能障碍的药效学作用,为CMS203片的临床用法、用量提供依据。
[Translation] The main objective is to evaluate the pharmacodynamic effects of different doses of CMS203 tablets on erectile dysfunction and provide a basis for the clinical usage and dosage of CMS203 tablets.
健康成年男性受试者单次和多次口服CMS203片的安全性、耐受性及药代动力学临床试验
[Translation] A clinical trial on the safety, tolerability and pharmacokinetics of single and multiple oral administration of CMS203 tablets in healthy adult male subjects
评估健康成年男性受试者空腹条件下单次和多次口服CMS203片的安全性和耐受性;评估健康成年男性受试者单次和多次口服递增剂量的CMS203片后的药代动力学特征;评估进食对健康成年男性受试者单次口服CMS203片药代动力学的影响。
[Translation] To evaluate the safety and tolerability of single and multiple oral administration of CMS203 tablets in healthy adult male subjects under fasting conditions; to evaluate the pharmacokinetic characteristics of single and multiple oral escalating doses of CMS203 tablets in healthy adult male subjects; and to evaluate the effect of food on the pharmacokinetics of a single oral administration of CMS203 tablets in healthy adult male subjects.
100 Clinical Results associated with Shanghai Zhongtuo Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Shanghai Zhongtuo Pharmaceutical Technology Co., Ltd.
100 Deals associated with Shanghai Zhongtuo Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Shanghai Zhongtuo Pharmaceutical Technology Co., Ltd.